BioStem Q2 FY26 GAAP net loss widens to $9 million; revenue rises 29% to $7.9 million vs Q1 - BSEM News | RalliesBioStem Q2 FY26 GAAP net loss widens to $9 million; revenue rises 29% to $7.9 million vs Q1
B
BSEM• Listing and full-year outlook
- BioStem was uplisted to the Nasdaq Capital Market on Aug. 7.
- Full-year 2026 revenue outlook was lifted to $26 million-$29 million.
Expenses increase on commercial expansion
- Operating expenses rise to $13.24 million, driven primarily by an expanding commercial team and infrastructure.
Q2 revenue rises sequentially while net loss widens
- BioStem posts Q2 2026 net revenue of $7.9 million, up 29% sequentially.
- GAAP swings to a net loss of $9 million, or $0.52 a share.
- Gross profit totals $4.84 million, with gross margin flat at 61% versus Q1 2026.
MHO
•
